Quince Therapeutics Inc Share Price Today: Live Updates & Key Insights

Quince Therapeutics Inc share price today is $0.086, up -8.78%. The stock opened at $0.0876 against the previous close of $0.0877, with an intraday high of $0.0948 and low of $0.0845.

Quince Therapeutics Inc Share Price Chart

Quince Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Quince Therapeutics Inc Share Price Performance

$0.086 -0.0878(-8.78%) QNCX at 23 Mar 2026 02:56 PM Biotechnology
Lowest Today 0.0845
Highest Today 0.0948
Today’s Open 0.0876
Prev. Close 0.0877
52 Week High 4.55
52 Week Low 0.08
Day’s Range: Low 0.0845 High 0.0948
52-Week Range: Low 0.08 High 4.55
1 day return -
1 Week return -16.39
1 month return -37.8
3 month return -97.65
6 month return -94.7
1 year return -93.78
3 year return -94.08
5 year return -99.76
10 year return -

Quince Therapeutics Inc Institutional Holdings

Nantahala Capital Management, LLC 4.80

Adage Capital Partners Gp LLC 4.04

Vanguard Group Inc 3.74

Woodline Partners LP 3.49

Vanguard Total Stock Mkt Idx Inv 2.67

Millennium Management LLC 2.14

IEQ CAPITAL, LLC 1.76

Almitas Capital LLC 1.67

StemPoint Capital LP 1.33

Renaissance Technologies Corp 0.97

Geode Capital Management, LLC 0.94

Jane Street Group LLC 0.94

Marshall Wace Asset Management Ltd 0.92

Vanguard Institutional Extnd Mkt Idx Tr 0.83

BlackRock Inc 0.62

Susquehanna International Group, LLP 0.62

HighTower Advisors, LLC 0.59

Fidelity Extended Market Index 0.43

683 Capital Management LLC 0.43

Union Square Park Capital Management, LLC 0.40

State Street Corp 0.36

HPM Partners LLC 0.34

Alphabet Inc 0.34

Blackrock Extended Mkt Fund CF 0.24

iShares Micro-Cap ETF 0.22

Extended Equity Market Fund K 0.21

Fidelity Total Market Index 0.15

Bridgeway Ultra-Small Company Market 0.13

Spartan Extended Market Index Pool F 0.12

Fidelity Series Total Market Index 0.12

NT Ext Equity Mkt Idx Fd - L 0.11

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - NL 0.08

Vanguard Instl Ttl Stck Mkt Idx Tr 0.07

Spartan Total Market Index Pool G 0.06

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.06

Vanguard Balanced Index Inv 0.05

Fidelity Nasdaq Composite Index 0.05

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.04

Vanguard U.S. Eq Idx £ Acc 0.04

Quince Therapeutics Inc Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Quince Therapeutics Inc Fundamentals

Market Cap 4.45 M

PB Ratio 4.6112

PE Ratio 0.0

Enterprise Value -3.41 M

Total Assets 114.48 M

Volume 14002668

Quince Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-28025000 -28.0M, FY22:-51660000 -51.7M, FY21:-89325000 -89.3M, FY20:-76849000 -76.8M, FY19:-36792000 -36.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-36000 -0.0M, Q2/2025:-35000 -0.0M, Q1/2025:-32000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-44000 -0.0M

Quarterly Net worth Q3/2025:-13442000 -13.4M, Q2/2025:-16049000 -16.0M, Q1/2025:-15030000 -15.0M, Q3/2024:-5492000 -5.5M, Q2/2024:-27729000 -27.7M

About Quince Therapeutics Inc & investment objective

Company Information Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 36

Industry Biotechnology

CEO Dr. Dirk Thye M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Quince Therapeutics Inc FAQs

What is the share price of Quince Therapeutics Inc today?

The current share price of Quince Therapeutics Inc is $0.086.

Can I buy Quince Therapeutics Inc shares in India?

Yes, Indian investors can buy Quince Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Quince Therapeutics Inc shares in India?

You can easily invest in Quince Therapeutics Inc shares from India by:

Can I buy fractional shares of Quince Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Quince Therapeutics Inc?

Quince Therapeutics Inc has a market cap of $4.45 M.

In which sector does Quince Therapeutics Inc belong?

Quince Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Quince Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Quince Therapeutics Inc?

The PE ratio of Quince Therapeutics Inc is N/A and the PB ratio is 4.61.